Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rieckmann

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension studyPeter Rieckmann, Robert Zivadinov, Alexey Boyko, et al.
Annals of the New York Academy of Sciences|June 24, 2008
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphismsPhilipp Ströbel, Wen-Yu Chuang, Sergei Chuvpilo, et al.
JAMA Neurology|July 6, 2016
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD StudyLudwig Kappos, David K B Li, Olaf Stüve, et al.
Annals of Neurology|January 31, 2003
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactateMarjo S van der Knaap, Patrick van der Voorn, Frederik Barkhof, et al.
Multiple Sclerosis International|January 24, 2014
Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countriesMohammed Aljumah, Raed Alroughani, I Alsharoqi, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Functional clinical outcomes in multiple sclerosis: Current status and future prospectsRana Karabudak, Maurice Dahdaleh, Mohammed Aljumah, et al.
Journal of Neuroimmunology|July 6, 2010
Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosisSandra Nischwitz, Sabine Cepok, Antje Kroner, et al.
Annals of Neurology|November 25, 2004
Selective loss of regulatory T cells in thymomasPhilipp Ströbel, Andreas Rosenwald, Niklas Beyersdorf, et al.
The Lancet. Neurology|June 15, 2013
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, David K B Li, Hans-Peter Hartung, et al.
European Journal of Human Genetics : EJHG|December 15, 2010
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing unitsTony Kam-Thong, Darina Czamara, Koji Tsuda, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension studyPeter Rieckmann, Robert Zivadinov, Alexey Boyko, et al.
Annals of the New York Academy of Sciences|June 24, 2008
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphismsPhilipp Ströbel, Wen-Yu Chuang, Sergei Chuvpilo, et al.
JAMA Neurology|July 6, 2016
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD StudyLudwig Kappos, David K B Li, Olaf Stüve, et al.
Annals of Neurology|January 31, 2003
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactateMarjo S van der Knaap, Patrick van der Voorn, Frederik Barkhof, et al.
Multiple Sclerosis International|January 24, 2014
Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countriesMohammed Aljumah, Raed Alroughani, I Alsharoqi, et al.
Multiple Sclerosis and Related Disorders|May 27, 2015
Functional clinical outcomes in multiple sclerosis: Current status and future prospectsRana Karabudak, Maurice Dahdaleh, Mohammed Aljumah, et al.
Journal of Neuroimmunology|July 6, 2010
Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosisSandra Nischwitz, Sabine Cepok, Antje Kroner, et al.
Annals of Neurology|November 25, 2004
Selective loss of regulatory T cells in thymomasPhilipp Ströbel, Andreas Rosenwald, Niklas Beyersdorf, et al.
The Lancet. Neurology|June 15, 2013
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 studyKrzysztof Selmaj, David K B Li, Hans-Peter Hartung, et al.
European Journal of Human Genetics : EJHG|December 15, 2010
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing unitsTony Kam-Thong, Darina Czamara, Koji Tsuda, et al.
Pageof 13